WebApr 12, 2024 · Natalie Grover and Jennifer Rigby. LONDON (Reuters) -Ghana has become the first country in the world to approve a new malaria vaccine from Oxford University, a potential step forward in fighting a disease that kills hundreds of thousands of children each year. The approval is unusual as it comes before the publication of final-stage trial data. WebMar 8, 2024 · No study visits or treatments will be given as part of the study. GSK considered adding a telemedicine component, Crouthamel said, but “we are wondering if we can make this truly digital” while still keeping participants and gathering valuable data. As a first step, the RISE study is offering participants compensation.
GSK catches up with Pfizer in MenABCWY vaccine race
Web1 day ago · GSK threw in the towel on its maternal immunization program last year due to safety concerns. However, the company announced positive results in October 2024 from a late-stage study evaluating its ... WebGSK's $100M ADC bet in doubt after fatality in first trial of Mersana's cancer therapy By James Waldron Mar 13, 2024 10:05am Mersana Therapeutics GSK antibody drug … signed first editions
Adaptimmune to regain rights to cancer drug programs from GSK
WebFeb 24, 2024 · The first scheduled trial expected next week, related to GSK Plc's (NYSE: GSK) Zantac associated with cancer, has been postponed, likely by several months. The case is expected to go to trial in ... WebSep 28, 2024 · GlaxoSmithKline plc (LSE/NYSE: GSK) today announced results from PRIMA (ENGOT-OV26/GOG-3012), the Phase 3 randomised, double-blind, placebo-controlled study of Zejula (niraparib) as a maintenance therapy in women with first-line ovarian cancer following a response to platinum-based chemotherapy. WebNov 24, 2024 · GlaxoSmithKline ( GSK) has initiated dosing of patients in the Phase III clinical programme evaluating the safety and efficacy of its Respiratory Syncytial Virus … signed flood notice